The original research embraced a holistic perspective by conducting three separate yet interrelated systematic reviews and meta-analyses, each examining distinct facets of psychedelic substances. The pharmacological review extensively cataloged and analyzed the biochemical interactions of classic psychedelics—compounds primarily acting on serotonergic systems such as the 5-HT2A receptor. This review meticulously compiled data across numerous studies, providing high-resolution insight into receptor binding affinities, dose-response relationships, and downstream neurochemical cascades. Such biochemical granularity is crucial for delineating the therapeutic windows and safety profiles of these agents, which have shown promise in treating mental health disorders including depression, anxiety, and PTSD.

Simultaneously, the neuroimaging meta-analysis harnessed neurofunctional and structural brain data derived from functional Magnetic Resonance Imaging (fMRI), Positron Emission Tomography (PET), and Magnetoencephalography (MEG). This layer of investigation revealed convergent patterns of brain activity modulation induced by psychedelics, such as enhanced connectivity within the default mode network (DMN), and decreased modular segregation across cortical regions. These neuroplasticity-related changes correlate strongly with altered states of consciousness and cognitive flexibility, offering mechanistic explanations for the reported subjective effects and long-term psychological benefits of psychedelic therapy. The synthesis of these imaging data across numerous cohorts marks a pivotal step in validating neurobiological models of psychedelic action.

Complementing these objective measures, the phenomenological review synthesized qualitative data from psychometric assessments, narrative reports, and validated consciousness scales. This branch of research illuminates the intricate landscape of subjective experience—including ego dissolution, mystical-type experiences, emotional breakthroughs, and perceptual distortions—that are central to both the cultural significance and clinical efficacy of psychedelics. By systematically categorizing and quantifying these lived experiences, the review bridges the gap between measurable brain alterations and their psychological manifestations, creating a cohesive framework by which subjective phenomenology can be scientifically scrutinized and therapeutically harnessed.

The integrative nature of this triadic research approach propels the understanding of psychedelics beyond isolated analyses into a multi-dimensional model that synergizes biochemical, neurophysiological, and psychological data. The correction published in Translational Psychiatry ensures that this model remains robust and reproducible, addressing previous data inconsistencies and methodological refinements that enhance the interpretability of results. The amended results reinforce the notion that psychedelics act as modulators of brain network dynamics and personal consciousness, with therapeutic implications that extend far beyond symptom alleviation to potential catalysis of enduring psychological transformation.

This revised synthesis underscores the importance of dosage calibration and individual variability, revealing that the interplay between neuropharmacological potency and experiential context is more nuanced than previously thought. Such insights stress personalized approaches in both research design and clinical protocols, advocating for adaptive titrations aligned with patient-specific neural and psychological profiles. The neurobiological markers identified through imaging studies could serve as predictive biomarkers for therapeutic responsiveness, streamlining patient selection and optimizing treatment outcomes.

Furthermore, the corrected data emphasizes the critical role of serotonin 2A receptor agonism as a nexus in initiating the psychedelic state, while also suggesting contributions from additional receptor systems and neuromodulatory circuits. This broader pharmacological perspective widens the scope for the development of next-generation psychedelics with tailored receptor profiles optimized for efficacy and tolerability. Insights garnered from molecular interaction studies may open pathways for the design of compounds that selectively engage cognitive and emotional circuits relevant to distinct psychiatric conditions.

One of the most compelling advancements lies in the elucidation of how psychedelics facilitate large-scale brain network reorganization. The reconfiguration of connectivity patterns observed in neuroimaging meta-analyses aligns with theoretical models proposing that psychedelics act as neurodynamic modulators. These substances appear to transiently reduce hierarchical constraints within cortical networks, thus enriching information flow and cognitive flexibility. By temporarily suspending entrenched neural and psychological patterns, psychedelics may provide windows of opportunity for therapeutic reprogramming of maladaptive mental states.

The phenomenological data corrected and refined within this framework present critical considerations for therapeutic applications, highlighting that the quality and integration of the psychedelic experience substantially influence clinical outcomes. Mystical-type experiences, characterized by feelings of unity and transcendence, consistently correlate with positive treatment effects, suggesting that subjective experience is not merely epiphenomenal but central to psychedelic efficacy. These findings underscore the necessity for skilled psychological guidance and supportive set and setting to maximize beneficial outcomes while minimizing risks.

Moreover, the meta-analytic approach strengthens the evidence base by mitigating sample heterogeneity and publication bias, thereby enhancing the generalizability and reliability of findings across diverse populations and psychedelic compounds. The inclusion of multiple psychedelic agents—such as psilocybin, LSD, DMT, and mescaline—within the analyzed datasets allows for comparative evaluations of their neurobiological and phenomenological profiles, clearly delineating commonalities and distinctive traits that can inform therapeutic stratification.

The correction further calls attention to the dynamic interplay between neuroplasticity and psychological insight engendered by psychedelics. Emerging evidence suggests that these substances potentiate synaptic plasticity and neurogenesis, mediated by key signaling pathways including brain-derived neurotrophic factor (BDNF). Such molecular mechanisms might explain the sustained psychological benefits observed long after the acute effects dissipate, supporting models of psychedelics as catalysts for profound neurocognitive remodeling.

Importantly, the updated integrative review emphasizes the translational potential of these findings, advocating for their incorporation into clinical trial design and psychiatric practice. By clarifying the multi-level mechanisms underpinning psychedelic action, the study provides a scientifically rigorous foundation to support regulatory frameworks and therapeutic protocols. This harmonized understanding could accelerate drug development pipelines and guide evidence-based policy-making, ultimately facilitating wider access to psychedelics in mental health care.

In the wake of these pivotal corrections, the scientific community is poised to refine experimental paradigms, embracing multi-modal methodologies that span molecular neuroscience, systems biology, and phenomenological inquiry. Future research will likely expand upon this groundwork, employing cutting-edge techniques such as high-resolution connectomics, real-time neurofeedback, and computational modeling to deepen mechanistic insights. Such endeavors promise to unravel the intricate tapestry of psychedelic effects with unprecedented precision.

In sum, this correction to the integrated series of systematic reviews and meta-analyses marks a landmark moment in psychedelic science. It not only rectifies previous ambiguities but also elevates a synergistic understanding that encompasses receptor pharmacodynamics, network-level brain modulation, and complex subjective experience. As the field progresses, these insights will be foundational to the responsible and effective clinical deployment of psychedelics, heralding an era of transformative mental health interventions grounded in rigorous, multi-disciplinary science.

Subject of Research: A synergistic, multi-level understanding of psychedelics, integrating pharmacology, neuroimaging, and phenomenology through systematic reviews and meta-analyses.

Article Title: Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Article References:
Shinozuka, K., Jerotic, K., Mediano, P. et al. Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. Transl Psychiatry 15, 470 (2025). https://doi.org/10.1038/s41398-025-03731-7

Image Credits: AI Generated

Obsessive-compulsive disorder (OCD) and related syndromes form a complex cluster of psychiatric conditions characterized by intrusive thoughts and repetitive ritualistic behaviors. Traditional treatments often fall short, especially in cases resistant to serotonin reuptake inhibitors. This review sharply focuses on psilocybin, the serotonergic psychedelic prodrug derived from Psilocybe mushrooms, spotlighting its potential beyond mood disorders into the realm of compulsive pathologies.

A notable highlight is the rapid, robust symptom relief observed across clinical cohorts following single doses of psilocybin. Remarkably, early studies from the mid-2000s reported significant reductions in symptom severity within hours, with some patients exhibiting near-complete remission. Such rapid onset challenges current pharmacotherapies that necessitate prolonged administration, and intriguingly, suggests that even lower psilocybin doses can produce therapeutic gains independent of classic dose-response trajectories.

The review extends its scope to include body dysmorphic disorder, a condition sharing neurobiological substrates with OCD, where psilocybin similarly attenuated distressing preoccupations and ritualistic behaviors. This transdiagnostic perspective implies that psilocybin’s mechanisms target core neurocircuitry dysfunctions underpinning compulsivity rather than disorder-specific symptoms, heralding a paradigm shift in psychiatric therapeutics.

Preclinical investigations lend compelling support through the employment of SAPAP3 knockout mice, a validated genetic model exhibiting pathological grooming behaviors akin to human OCD. Single doses of psilocybin administered in these models yielded enduring mitigation of compulsive actions, with effects persisting weeks to over a month. This contrasts starkly with transient benefits noted in wild-type rodents and highlights psilocybin’s potential for inducing sustained neurobiological recalibration within maladaptive frontostriatal circuits.

Underlying these behavioral patterns are tantalizing mechanistic clues that challenge traditional serotonergic paradigms. Psilocybin’s active metabolite, psilocin, is a potent 5-HT2A receptor agonist responsible for psychedelic phenomenology. Yet intriguingly, multiple studies demonstrated that antagonism of 5-HT2A receptors did not abolish psilocybin’s anti-compulsive effects in animal models, suggesting alternative or complementary pathways at play. Such findings open the door to the development of non-hallucinogenic analogs capable of dissociating therapeutic efficacy from psychedelic experiences, with significant implications for clinical scalability and patient accessibility.

The molecular landscape further reveals psilocybin’s potent induction of neuroplasticity markers. Acute administration upregulates immediate early genes and synaptic scaffolding proteins, promoting dendritic spine growth in the medial prefrontal cortex and enhancing excitatory neurotransmission. These synaptic modifications likely underpin the enduring behavioral alleviations observed, offering a neuroanatomical substrate for circuit-level normalization in compulsive disorders.

Amid these advances, critical limitations temper enthusiasm. Clinical studies suffer from small sample sizes, lack of placebo controls, and heterogeneity in dosing protocols, impeding definitive efficacy assessments. Similarly, the scarcity of neuroimaging data leaves open questions regarding circuit-level changes correlating with clinical response. Furthermore, sex differences in treatment outcomes remain an underexplored but crucial dimension, given established disparities in OCD presentation and prognosis.

The review also delineates discrepancies in chronic dosing paradigms. Low-dose continuous administration in wild-type rats fostered synaptic plasticity and modest behavioral improvements, whereas chronic regimens failed to ameliorate compulsive phenotypes in SAPAP3 knockout mice. These divergent outcomes highlight the necessity of tailored dosing strategies and caution against extrapolating across species and models without nuance.

Looking forward, the authors advocate rigorous, placebo-controlled clinical trials powered sufficiently to parse out moderators of response, including symptom subtype, sex, and neurobiological characteristics. Incorporation of functional neuroimaging will be essential to elucidate psilocybin’s impact on frontostriatal hyperactivity. Concurrently, mechanistic preclinical studies employing receptor antagonism, protein synthesis inhibition, and synaptic quantification will be pivotal in elucidating the molecular underpinnings of sustained therapeutic effects.

Moreover, the role of psychological support frameworks accompanying psilocybin administration merits systematic investigation. Disentangling pharmacological effects from psychotherapeutic components will inform best practices and optimize integration protocols. Should non-hallucinogenic analogs retain efficacy independent of subjective psychedelic experiences, treatment paradigms could shift dramatically toward streamlined, less resource-intensive delivery models.

Fundamentally, this review heralds a new chapter in the psychopharmacology of compulsive disorders, tying together molecular, behavioral, and clinical threads into a coherent tapestry. It challenges entrenched notions about the necessity of hallucinogenic effects for therapeutic benefit, spotlights the translational validity of genetic animal models, and charts a bold research roadmap to propel psilocybin from promising substance to proven medicine.

In summary, the systematic synthesis of clinical and preclinical evidence crystallizes psilocybin’s potential as a uniquely rapid-acting, durable treatment for OCD and related compulsive disorders. It underscores the urgency of expanding well-controlled trials, deepening mechanistic insights, and refining therapeutic protocols to unlock the full promise of psychedelics in neuropsychiatry. This work sets a new benchmark, uniting the voices of mice and humans in a shared circuit language that may ultimately rewrite the neurobiology of compulsivity.

Subject of Research: People

Article Title: Psilocybin’s effects on obsessive-compulsive behaviours: A systematic review of preclinical and clinical evidence

News Publication Date: 28-Oct-2025

Web References: https://doi.org/10.61373/pp025i.0044

Image Credits: Julio Licinio / Depositphotos, extended license

Keywords: psilocybin, obsessive-compulsive disorder, compulsive behavior, neuroplasticity, SAPAP3 knockout mice, psychedelics, serotonin receptors, 5-HT2A receptor, frontostriatal circuits, body dysmorphic disorder, preclinical models, psychiatric therapeutics